|Bid||8.41 x 2900|
|Ask||8.80 x 4000|
|Day's range||8.09 - 8.75|
|52-week range||8.09 - 20.45|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.50|
The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.
Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 15.00% and -7.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?